Crinetics Pharmaceuticals CRNX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $102.34M-61.5% | $265.85M+373% | $56.2M+72.0% | $32.67M-83.7% | ||
| $926.35M-15.0% | $1.09B+116% | $503.66M+66.9% | $301.75M+127% | ||
| —— | $0— | $0— | —— | ||
| —— | $0— | $0— | —— | ||
| $1.05B-23.8% | $1.38B+140% | $574.15M+66.3% | $345.18M+0.1% | ||
| $14.3M+18.5% | $12.07M+10.9% | $10.88M+211% | $3.5M+23.9% | ||
| $1.13B-21.5% | $1.43B+126% | $635.35M+80.4% | $352.18M+0.3% | ||
| $22.61M+286% | $5.85M-74.8% | $23.2M+51.1% | $15.35M+81.3% | ||
| $1.24M-43.2% | $2.18M+5.8% | $2.06M-8.2% | $2.24M— | ||
| $85.07M+42.5% | $59.68M+35.8% | $43.94M+58.5% | $27.72M+73.3% | ||
| $134.17M+22.2% | $109.79M+14.1% | $96.25M+168% | $35.85M+88.0% | ||
| 200M-91.2% | 2.3B+91.0% | 1.2B+56.9% | 759.4M+25.0% | ||
| -$1.42B-48.9% | -$952.11M-45.6% | -$653.7M-48.8% | -$439.17M-59.6% | ||
| $992.08M-25.1% | $1.32B+146% | $539.11M+70.4% | $316.33M-4.7% | ||
| $1.13B-21.5% | $1.43B+126% | $635.35M+80.4% | $352.18M+0.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Crinetics Pharmaceuticals cover its short-term obligations?
- Its current ratio is 18.60 — current assets exceed current liabilities.
- Where does Crinetics Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.